Kaposi's sarcoma-associated herpesvirus virion-induced transcription activation of the ORF50 immediate-early promoter.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 1235868)

Published in J Virol on October 01, 2005

Authors

Fang Lu1, Latasha Day, Paul M Lieberman

Author Affiliations

1: The Wistar Institute, Philadelphia, PA 19104, USA.

Articles cited by this

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81

Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11

In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood (1995) 6.91

A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76

Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71

Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components. J Virol (1985) 5.47

Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology (1998) 5.43

Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45

Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N Engl J Med (1997) 3.90

Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61

Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol (2004) 3.57

Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (1998) 3.54

Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50

Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol (2002) 3.41

Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest (2004) 3.39

Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell (2002) 3.35

Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02

Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90

The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci (2003) 2.85

KSHV and Kaposi's sarcoma: the end of the beginning? Cell (1997) 2.68

Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (2003) 2.60

The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev (2002) 2.59

De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol (2002) 2.55

A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol (2000) 2.37

UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc Natl Acad Sci U S A (2000) 2.36

Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20

Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus. J Gen Virol (2000) 2.17

Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol (2001) 2.13

Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J Virol (2003) 2.04

CREB-binding protein and histone deacetylase regulate the transcriptional activity of Kaposi's sarcoma-associated herpesvirus open reading frame 50. J Virol (2001) 1.96

Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol (2002) 1.94

Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res (2004) 1.88

Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83

CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol (2003) 1.72

Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol (2003) 1.70

Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70

Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev (2002) 1.67

Regulation of human cytomegalovirus immediate-early gene expression. Intervirology (1996) 1.58

Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J Virol (2004) 1.51

The restricted cellular host range of human herpesvirus 8. AIDS (2000) 1.41

Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J Virol (2003) 1.32

The alpha promoter regulator-ovalbumin chimeric gene resident in human cells is regulated like the authentic alpha 4 gene after infection with herpes simplex virus 1 mutants in alpha 4 gene. Cell (1983) 1.23

Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Res (2002) 1.17

Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events. Blood (2002) 1.07

Herpes simplex virus type 1 tegument protein VP22 interacts with TAF-I proteins and inhibits nucleosome assembly but not regulation of histone acetylation by INHAT. J Gen Virol (2003) 1.05

Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology (2002) 1.01

HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer (2002) 0.97

Articles by these authors

Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J (2008) 4.28

TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell (2009) 2.60

The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol (2004) 2.13

Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol (2010) 1.98

ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol (2004) 1.97

Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. J Virol (2008) 1.86

Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell (2002) 1.76

Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70

Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. J Virol (2006) 1.57

Cell cycle regulation of chromatin at an origin of DNA replication. EMBO J (2005) 1.40

Snapshots: chromatin control of viral infection. Virology (2013) 1.39

An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe (2012) 1.38

ORC binding to TRF2 stimulates OriP replication. EMBO Rep (2006) 1.38

RNA-dependent recruitment of the origin recognition complex. EMBO J (2008) 1.37

The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol (2007) 1.36

Chromatin profiling of Epstein-Barr virus latency control region. J Virol (2007) 1.34

Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus. J Virol (2004) 1.33

Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment. J Virol (2009) 1.29

CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog (2010) 1.27

Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. J Virol (2003) 1.27

Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF. J Virol (2006) 1.24

A role for CTCF and cohesin in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J (2012) 1.21

Epigenetic control of replication origins. Cell Cycle (2005) 1.19

Coordination of KSHV latent and lytic gene control by CTCF-cohesin mediated chromosome conformation. PLoS Pathog (2011) 1.16

Timeless preserves telomere length by promoting efficient DNA replication through human telomeres. Cell Cycle (2012) 1.16

EBV latency types adopt alternative chromatin conformations. PLoS Pathog (2011) 1.15

EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog (2011) 1.14

Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome. Proc Natl Acad Sci U S A (2013) 1.13

Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta (2009) 1.12

Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol (2010) 1.09

Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency. J Virol (2012) 1.08

Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol (2005) 1.06

Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05

A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol (2005) 1.04

Cell cycle control of Kaposi's sarcoma-associated herpesvirus latency transcription by CTCF-cohesin interactions. J Virol (2009) 1.03

Epstein-Barr virus episome stability is coupled to a delay in replication timing. J Virol (2008) 1.02

TERRA, CpG methylation and telomere heterochromatin: lessons from ICF syndrome cells. Cell Cycle (2010) 1.01

14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Res (2010) 1.01

Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Dev Cell (2013) 1.01

Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol J (2010) 1.00

Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1. J Virol (2010) 0.96

The CBP bromodomain and nucleosome targeting are required for Zta-directed nucleosome acetylation and transcription activation. Mol Cell Biol (2003) 0.96

Epstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication. J Virol (2008) 0.96

Molecular basis for oligomeric-DNA binding and episome maintenance by KSHV LANA. PLoS Pathog (2013) 0.95

DNA affinity purification of Epstein-Barr virus OriP-binding proteins. Methods Mol Biol (2005) 0.95

A role for MRE11, NBS1, and recombination junctions in replication and stable maintenance of EBV episomes. PLoS One (2007) 0.94

Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One (2010) 0.94

Mechanism of glycyrrhizic acid inhibition of Kaposi's sarcoma-associated herpesvirus: disruption of CTCF-cohesin-mediated RNA polymerase II pausing and sister chromatid cohesion. J Virol (2011) 0.93

CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation. Nucleic Acids Res (2013) 0.92

Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1. J Biomol Screen (2010) 0.91

CTCF regulates Kaposi's sarcoma-associated herpesvirus latency transcription by nucleosome displacement and RNA polymerase programming. J Virol (2012) 0.90

Epigenetic regulation of EBV and KSHV latency. Curr Opin Virol (2013) 0.90

Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. J Cell Sci (2012) 0.88

Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni. Biochemistry (2011) 0.88

Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J Virol (2008) 0.87

Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data. Viruses (2013) 0.86

Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site. J Virol (2013) 0.85

The replisome pausing factor Timeless is required for episomal maintenance of latent Epstein-Barr virus. J Virol (2011) 0.84

Timeless links replication termination to mitotic kinase activation. PLoS One (2011) 0.84

Timeless-dependent DNA replication-coupled recombination promotes Kaposi's Sarcoma-associated herpesvirus episome maintenance and terminal repeat stability. J Virol (2013) 0.84

Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres. Cancer Biol Ther (2009) 0.84

Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism. Future Virol (2010) 0.82

Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents. Org Biomol Chem (2012) 0.81

Regulation of Epstein-Barr virus origin of plasmid replication (OriP) by the S-phase checkpoint kinase Chk2. J Virol (2010) 0.81

Bioactive activities of natural products against herpesvirus infection. J Microbiol (2013) 0.81

Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol (2010) 0.81

Telomeres and viruses: common themes of genome maintenance. Front Oncol (2012) 0.80

Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain. J Virol (2006) 0.80

Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter. J Virol (2004) 0.78

Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. ACS Chem Biol (2014) 0.77

Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation. J Virol (2009) 0.77

Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening. Expert Opin Drug Discov (2010) 0.75